Visual Impairment News and Research

Latest Visual Impairment News and Research

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

30 Apr 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.

22 Apr 2011

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.

15 Apr 2011

Middle-aged adults with diabetes more likely to develop age-related ailments

Middle-aged adults with diabetes are much more likely to develop age-related conditions than their counterparts who don't have diabetes, according to a new study by the University of Michigan Health System and VA Ann Arbor Healthcare System.

1 Apr 2011

Researchers create hiPS-RPE cells to treat age-related macular degeneration

The notion of transplanting adult stem cells to treat or even cure age-related macular degeneration has taken a significant step toward becoming a reality. In a study published today in Stem Cells, Georgetown University Medical Center researchers have demonstrated, for the first time, the ability to create retinal cells derived from human-induced pluripotent stem cells that mimic the eye cells that die and cause loss of sight.

24 Mar 2011

Anthem Life sponsors USABA to host Winter Ski Festival for visually impaired athletes

Sponsored by Anthem Life Insurance Company, The United States Association of Blind Athletes is pleased to host the second annual Colorado Winter Ski Festival in Breckenridge, CO, from Friday, March 11 through Monday, March 14.

5 Mar 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

Study explores levels of burden and depression in caregivers with sensory impairment

When a person experiences impairment or declining health, caregiving typically falls to a family member, most often a spouse. This increased burden can cause burnout, stress, and illness in the caregiver. The health care system focuses first on the client and provides little support for the caregiver.

14 Feb 2011

Doctors of Optometry troubled by disregard for vision and eye health needs of children

The American Optometric Association, the voice of America's family eye doctors, today warned that if a set of U.S. Preventive Services Task Force recommendations are adopted as policy, significant harm will be caused to the ongoing efforts of eye doctors nationwide to reverse the high rates of preventable vision loss in children across America, from the first year of life through age 5.

5 Feb 2011

Patients and spouses experience distress related to diabetes

Older patients with diabetes who are not dealing well with the disease are likely to have symptoms of depression, and spouses of older patients also suffer distress related to diabetes and its management, according to research from Purdue University.

28 Jan 2011

What protects certain diabetics from complications?

Much research has been carried out on why diabetics develop complications. Now researchers are asking the question the other way around. They want to know why some diabetic patients do not develop complications. What is it that protects them? The PROLONG study could provide the answer.

21 Jan 2011

AER changes journal name to Insight: Research and Practice in Visual Impairment and Blindness

With its mission of providing insight into issues surrounding blindness, the journal of the Association for Education and Rehabilitation of the Blind and Visually Impaired (AER) will now express that vision in its name. Insight: Research and Practice in Visual Impairment and Blindness has been the journal's new title as of January 1, 2011.

20 Jan 2011

EDMA to endorse the campaign on Hypoparathyroidism

On the occasion of the World Hypoparathyroidism Awareness Day 2011, EDMA, the European Diagnostic Manufacturers Association, highlights the crucial role the In Vitro Diagnostic (IVD) industry can play to effectively testing this rare endocrine condition.

5 Jan 2011

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

QLT Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for QLT091001, its oral synthetic retinoid, for the treatment of Leber Congenital Amaurosis (LCA). LCA is an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.

8 Dec 2010

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.

8 Dec 2010

Early eye exam can save sight and prevent a life time disability

Jennifer Hartman had no idea her child had a significant vision problem. The day after her daughter's sixth birthday, after an eye exam, she was diagnosed as being legally blind in one eye with a condition called amblyopia or lazy eye.

1 Dec 2010

Phase 3 trial: TYSABRI improves vision in MS patients

Results recently presented from a study of multiple sclerosis (MS) patients taking TYSABRI (natalizumab) are supported by a Canadian woman's improved vision since starting the therapy.

25 Nov 2010

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

QLT Inc. today announced expansion of the Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber Congenital Amaurosis (LCA) to include patients with Retinitis Pigmentosa (RP), a set of hereditary retinal diseases demonstrating clinical features similar to LCA.

28 Oct 2010

Cataract surgery also reduces car crashes

Cataract surgery not only improves vision and quality of life for older people, but is also apparently a way to reduce the number of car crashes. The research will be presented today's at the Scientific Program of the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

20 Oct 2010

Falls are the leading cause of ER visits and unintentional home injury deaths

If you or someone you know has been treated in the emergency department recently after suffering a fall, you are not alone. Unintentional falls are the leading injury-related reason for why people seek emergency care, with almost 9 million visits occurring each year, according to the latest data from the Centers for Disease Control and Prevention.

20 Oct 2010

Visual Impairment News and Research

Latest Visual Impairment News and Research

Gene therapy approach using CD59 shows promise against AMD: Study

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Middle-aged adults with diabetes more likely to develop age-related ailments

Researchers create hiPS-RPE cells to treat age-related macular degeneration

Anthem Life sponsors USABA to host Winter Ski Festival for visually impaired athletes

Phase III RISE study of Lucentis for DME meets primary endpoint

Study explores levels of burden and depression in caregivers with sensory impairment

Doctors of Optometry troubled by disregard for vision and eye health needs of children

Patients and spouses experience distress related to diabetes

What protects certain diabetics from complications?

AER changes journal name to Insight: Research and Practice in Visual Impairment and Blindness

EDMA to endorse the campaign on Hypoparathyroidism

QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

Early eye exam can save sight and prevent a life time disability

Phase 3 trial: TYSABRI improves vision in MS patients

QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa

Cataract surgery also reduces car crashes

Falls are the leading cause of ER visits and unintentional home injury deaths

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Visual Impairment News and Research

Latest Visual Impairment News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in